Noviop (Latanoprost)

Latanoprost, the active ingredient in Noviop, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension. GNH USA supplies Noviop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Noviop is a prostaglandin analog indicated for conditions that require reduction of intra‑ocular pressure. - Open-angle glaucoma: lowers intra‑ocular pressure to slow disease progression. - Ocular hypertension: reduces elevated eye pressure to prevent development of glaucoma. - Pseudoexfoliative glaucoma: improves aqueous outflow to control pressure.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual brownish pigmentation. - Eye irritation: foreign‑body sensation or mild discomfort. - Blurred vision: transient visual disturbance. - Dry eye: reduced tear production.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract. - Macular edema: fluid accumulation affecting central vision. - Vision loss: sudden decrease in visual acuity. - Ocular infection: signs of bacterial or fungal involvement.

Before initiating therapy, clinicians should consider several safety aspects. - Monitor intra‑ocular pressure: ensure target reduction is achieved. - Assess for ocular inflammation: avoid use if active uveitis is present. - Avoid in patients with known hypersensitivity to latanoprost or excipients. - Caution in corneal disease: may exacerbate epithelial defects. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent prostaglandin analogs: increased risk of ocular side effects. - Systemic carbonic anhydrase inhibitors: additive intra‑ocular pressure lowering effect; monitor closely.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may reduce latanoprost efficacy. - Beta‑blocker eye drops: additive pressure‑lowering effect; observe for excessive reduction. - Alpha‑agonist eye drops: potential for enhanced pressure decrease; adjust therapy as needed.